^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SF3B1 mutation

    i
    Other names: SF3B1, Splicing Factor 3b Subunit 1, Splicing Factor 3b Subunit 1 155kDa, Spliceosome-Associated Protein 155, Splicing Factor 3B Subunit 1, SF3b155, SAP155, Pre-MRNA Splicing Factor SF3b 155 KDa Subunit, Pre-MRNA-Splicing Factor SF3b 155 KDa Subunit, Splicing Factor 3b Subunit 1 155kD, Pre-MRNA Processing 10, SAP 155, Hsh155, PRPF10, PRP10, MDS
    Entrez ID:
    23451
    Related biomarkers:
    Mutation
    Others
    Apply
    Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms (NCT05732961)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    02/21/2023
    Primary completion :
    06/20/2025
    Completion :
    09/01/2025
    SF3B1
    |
    SF3B1 mutation
    |
    Reblozyl (luspatercept-aamt)
    Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) (NCT04447651)
    Phase N/A
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    08/02/2024
    Initiation :
    09/17/2020
    Primary completion :
    08/01/2025
    Completion :
    08/01/2025
    SF3B1 • SRSF2 • U2AF1
    |
    SF3B1 mutation • SRSF2 mutation • U2AF1 mutation
    A Study of E7820 in People With Bone Marrow (Myeloid) Cancers (NCT05024994)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    08/13/2021
    Primary completion :
    08/01/2025
    Completion :
    08/01/2025
    FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2
    |
    IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation
    |
    E7820
    A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India (NCT05891249)
    Phase 4
    Bristol-Myers Squibb
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    06/05/2023
    Primary completion :
    04/13/2026
    Completion :
    04/13/2026
    SF3B1
    |
    SF3B1 mutation
    |
    Reblozyl (luspatercept-aamt)
    Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (NCT03418038)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    03/23/2018
    Primary completion :
    12/01/2025
    Completion :
    03/01/2026
    IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2
    |
    IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • cyclophosphamide intravenous • dexamethasone injection • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    AZD6738 for Patients With Progressive MDS or CMML (NCT03770429)
    Phase 1
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    08/05/2019
    Primary completion :
    05/31/2024
    Completion :
    05/31/2025
    SF3B1 • SRSF2 • U2AF1 • ZRSR2
    |
    SF3B1 mutation
    |
    ceralasertib (AZD6738)
    Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS (NCT04278768)
    Phase 1/2
    Curis, Inc.
    Recruiting
    Last update posted :
    03/11/2024
    Initiation :
    07/06/2020
    Primary completion :
    04/01/2026
    Completion :
    04/01/2026
    FLT3 • SF3B1 • U2AF1
    |
    FLT3 mutation • SF3B1 mutation • U2AF1 mutation
    |
    Venclexta (venetoclax) • azacitidine • emavusertib (CA-4948)
    RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL) (NCT05405309)
    Phase 1/2
    University of Utah
    Recruiting
    Last update posted :
    02/13/2024
    Initiation :
    09/23/2022
    Primary completion :
    08/15/2025
    Completion :
    08/15/2027
    TP53 • BCL2 • CD20 • SF3B1 • CCND1 • CD5 • POT1 • FCER2
    |
    TP53 mutation • ATM mutation • Chr t(11;14) • SF3B1 mutation
    |
    Lynparza (olaparib) • camonsertib (RP-3500)
    Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT03204188)
    Phase 2
    National Heart, Lung, and Blood Institute (NHLBI)
    Active, not recruiting
    Last update posted :
    11/28/2023
    Initiation :
    09/22/2017
    Primary completion :
    07/18/2022
    Completion :
    12/31/2026
    TP53 • SF3B1
    |
    TP53 mutation • NOTCH1 mutation • SF3B1 mutation
    |
    Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • fludarabine IV
    Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. (LUSPLUS) (NCT05181592)
    Phase 3
    GWT-TUD GmbH
    Recruiting
    Last update posted :
    10/12/2023
    Initiation :
    10/27/2021
    Primary completion :
    12/31/2024
    Completion :
    06/30/2025
    SF3B1
    |
    SF3B1 mutation • Chr del(5q)
    |
    Reblozyl (luspatercept-aamt)
    Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma (NCT05983237)
    Phase 1/2
    Jun Guo
    Not yet recruiting
    Last update posted :
    08/11/2023
    Initiation :
    08/31/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    SF3B1
    |
    SF3B1 mutation
    |
    temozolomide • AiRuiKa (camrelizumab) • AiRuiYi (fluzoparib)